An insight into the recent diabetes trials: What is the best approach to prevent macrovascular and microvascular complications?

Current Diabetes Reviews

Volumn 9, Issue 5, 2013, Pages 371-381

  Konig, Manige ^a   Lamos, Elizabeth Mary ^a   Stein, Stephanie Aleskow ^a   Davis, Stephen N ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

ACCORD; ADVANCE; BARI 2D; Diabetes trials; Intensive glycemic control; Macrovascular disease; ORIGIN; VADT

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; INSULIN GLARGINE; METFORMIN; SIMVASTATIN; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MACROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG COMBINATIONS; GLICLAZIDE; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDAPAMIDE; PERINDOPRIL;

EID: 84882756720     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/15733998113099990077     Document Type: Article

References (49)

1. National Center for Chronic Disease Prevention and Health Promotion. Diabetes Successes and Opportunities for Population-Based Prevention and Control at a Glance 2011. 2012; Available at: http://www.cdc.gov/diabetes. Accessed November 27, 2012.
2. World Health Organization. Diabetes Fact Sheet. 2012; Available at: http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed November 27, 2012.
3. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 2001; 249: 225-235.
4. Hanefeld M, Fischer S, Schmechel H, et al. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991; 14:308-317.
5. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998; 21: 1167-1172.
6. Wilson PW, Cupples LA, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J 1991; 121: 586-590.
7. Badimon L, Martinez-Gonzalez J, Llorente-Cortes V, Rodriguez C, Padro T. Cell biology and lipoproteins in atherosclerosis. Curr Mol Med 2006; 6: 439-456.
8. Badimon L, Vilahur G, Padro T. Lipoproteins, platelets and atherothrombosis. Rev Esp Cardiol 2009; 62: 1161-1178.
9. Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011; 105: S34-42.
10. Badimon L, Vilahur G. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. Ann N Y Acad Sci 2012; 1254: 18-32.
11. Inzucchi, SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient centered approach. Diabetes Care. 2012; 35: 1364-79.
12. Executive summary: Standards of medical care in diabetes--2010. Diabetes Care 2010; 33: S4-10.
13. Huisman TH, Martis EA, Dozy A. Chromatography of hemoglobin types on carboxymethylcellulose. J Lab Clin Med 1958; 52: 312-327.
14. Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun 1969; 36: 838-843.
15. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976; 295: 417-20.
16. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-1685.
17. Gibbons GW, Shaw PM. Diabetic vascular disease: characteristics of vascular disease unique to the diabetic patient. Semin Vasc Surg 2012; 25: 89-92.
18. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 12; 352: 854-865.
19. Ceriello A. Hypothesis: the metabolic memory, the new challenge of diabetes. Diabetes Res Clin Pract 2009; 86: S2-6.
20. Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The metabolic memory: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009; 94: 410-415.
21. Ceriello A, Esposito K, Ihnat M, Thorpe J, Giugliano D. Long-term glycemic control influences the long-lasting effect of hyperglycemia on endothelial function in type 1 diabetes. J Clin Endocrinol Metab 2009; 94: 2751-2756.
22. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
23. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
24. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
25. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedwald WT. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828.
26. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
27. NHLBI statement on use of rosiglitazone in two NHLBI-funded clinical trials. Available at: http://www.nhlbi.nih.gov/news/pressreleases/ 2007/nhlbi-statement-on-use-of-rosiglitazone-in-two-nhlbifunded-clinical-trials.html. Accessed June 19, 2013.
28. Meguro S, Shigihara T, Kabeya Y, Tomita M, Atsumi Y. Increased risk of renal deterioration associated with low e-GFR in type 2 diabetes mellitus only in albuminuric subjects. Intern Med 2009; 48: 657-663.
29. Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996; 19: 1243-1248.
30. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-44.
31. Keech AC, Mitchell P, Summanen PA, et al. Effects of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007; 370: 1687-97.
32. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
33. Zoungas S, Patel A, Chalmers J, de Galan BE, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418.
34. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
35. BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515.
36. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, Pichard AD, Kent KM, Satler LF, Wu H, Popma JJ, Leaon MB. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-589.
37. Kronmal RA, Barzilay JI, Tracy RP, Savage PJ, Orchard TJ, Burke GL. The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. J Clin Endocrinol Metab 2004; 89: 2852-2858.
38. Gerstein HC, Bosch J, Dagenais GR, et al. ORIGIN Trial Investigators, Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.
39. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
40. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009; 19: 604-12.
41. Buehler AM, Cavalcanti AB, Berwanger O, et al. Cardiovasc Ther 2013; 31: 147-60.
42. Sitagliptin cardiovascular outcome study (TECOS). Available at: http://clinicaltrials.gov/show/NCT00790205. Accessed June 19, 2013.
43. Cardiovascular outcomes study of alogliptin in subjects with type 2 diabetes and acute coronary syndrome (EXAMINE). Available at: http://clinicaltrials.gov/ct2/show/NCT00968708?term=EXAMINE&rank=1. Accessed June 19, 2013.
44. Does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications (SAVOR-TIMI 53). Available at: http://clinicaltrials.gov/ct2/show/NCT01107886?term=SAVOR&ra nk=1. Accessed June 19, 2013.
45. CAROLINA: Cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. Available at: http://clinicaltrials.gov/ct2/show/NCT01243424?term=cardiovascular+outcomes+study+of+the+DPP-4+inhibitor&rank=3. Accessed June 19, 2013.
46. Exanatide study of cardiovascular event lowering trial (EXSCEL): A trial to evaluate cardiovascular outcomes after treatment with exanatide once weekly in patients with type 2 diabetes mellitus. Available at: http://clinicaltrials.gov/ct2/show/NCT01144338? term=EXS CEL&rank=1. Accessed June 19, 2013.
47. CANVAS-Canagliflozin cardiovascular assessment study. Available at: http://clinicaltrials.gov/ct2/show/NCT01032629?term=CANVAS&rank=1. Accessed June 19, 2013.
48. Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with typw 2 diabetes. Diabetes Care 2007; 30: 1374-83.
49. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-75.